You are here: Home / Inflammation / Therapy / Developing new therapies

Developing new therapies

Members of the Cluster and the Center for Inflammation Medicine (CCIM) play a leading role in many multicenter clinical trials in the field of inflammation. In addition, our researchers are involved in the development of pharmaceuticals, treatment methods and diagnostic methods.

Chronic inflammations are even today, despite major advances, difficult to treat and are considered incurable. Serious side affects often occur with conventional treatments, which are based on immunosuppressive pharmaceuticals.

Members of the Cluster of Excellence are not only in charge of clinical trials for various new active biological ingredients, but in fact develop their own innovative forms of therapy.

sgp130fc – A new active pharmaceutical ingredient (API) for blocking the effects of IL-6

With sgp130fc, scientists from the Cluster have developed and patented a promising new API. Unlike many other anti-inflammatory pharmaceuticals, sgp130fc promises to only have an effect on chronic inflammatory processes and not lead to a general weakening of the immune system. The therapeutic benefit of sgp130Fc has been demonstrated in many animal models. Phase I clinical trials have demonstrated the safety of sgp130Fc in healthy humans. In a multinational Phase II study, the drug sgp130Fc (olamkicept) has been tested in people with ulcerative colitis since 2017.

Immunoadsorption as a therapy for diseases triggered by autoantibodies

Besides the development of sgp130fc, researchers from the Excellence Cluster are also involved in the development of methods for immunoadsorption, or rather, specific immunoadsorption (adsorption of antibodies, or rather, autoantibodies) in severe diseases such as blistering autoimmune dermatosis.

Document Actions